초록 열기/닫기 버튼
Background and Objectives The objective of this study was to investigate the effect of anactive transcutaneous bone conduction implant (BCI) of Bonebridge (MED-EL) on tinnituspatients with asymmetric hearing loss (AHL) or single-sided deafness (SSD). Subjects and Method Medical records and tinnitus questionnaires were reviewed retrospectivelyof patients with AHL or SSD, who received Bonebridge by a single surgeon at SeoulSt. Mary’s Hospital from 2017 to 2021. Audiologic evaluation and tinnitus questionnaires wereconducted before and after surgery. Results Of the 17 patients, 8 patients had SSD and 9 patients had AHL, and 13 patients(76.47%) had tinnitus before surgery while 4 patients did not. No patient showed newly developedtinnitus after surgery. After implantation, three patients (23.08%) showed a completeresolution of tinnitus. All patients showed significant improvement in hearing level after surgery. The mean tinnitus handicap inventory (THI) score and visual analogue scale (VAS) scorefor effect on life showed a significant decrease after surgery, from 43.1±28.2 to 29.7±25.7(p<0.05), and 4.7±2.9 to 3.2±3.3 (p<0.05), respectively. The mean THI scores of seven AHLpatients and seven patients with tinnitus on the implanted ear were significantly decreased afterimplantation from 50.9±24.7 to 34.6±27.5 (p<0.05) and from 53.1±23.4 to 37.4±15.0 (p<0.05),respectively. Conclusion BCI seems to be effective in suppressing tinnitus in the patients with AHL butnot with SSD. Along with directive counseling, sound therapy with Bonebridge can decreasetinnitus in some patients with AHL.
